Stockholders' Equity (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| Stockholders' Equity |
|
| Schedule of key assumptions to determine fair value of options |
| | | | | | | | | Three Months Ended | | | | | March 31, | | | | | 2026 | | 2025 | | | Average volatility | | 43.4 | % | 40.8 | % | | Average risk-free interest rate | | 3.9 | % | 4.2 | % | | Weighted-average expected life in years | | 6.3 | | 6.3 | | | Dividend yield rate | | — | % | — | % | |
|
| Schedule of the summary of option activity under all plans |
| | | | | | | | | | | | | | | | | | Weighted-Average | | | | | | | | Weighted-Average | | Remaining | | Aggregate | | | | | Exercise | | Contractual | | Intrinsic | | | Options | | Price | | Term (Years) | | Value(1) | | | | | | | | | | (in thousands) | Outstanding as of December 31, 2025 | | 6,884,390 | | $ | 25.75 | | | | | | Options granted | | 1,678,489 | | | 19.21 | | | | | | Options exercised | | (156,499) | | | 11.82 | | | | | | Options forfeited | | (23,048) | | | 35.65 | | | | | | Options expired | | (396,651) | | | 21.97 | | | | | | Outstanding as of March 31, 2026 | | 7,986,681 | | $ | 24.81 | | 6.40 | | $ | 8,868 | Exercisable as of March 31, 2026 | | 4,914,135 | | | 24.44 | | 4.60 | | $ | 8,230 | Vested and expected to vest as of March 31, 2026 | | 7,707,421 | | | 24.85 | | 6.29 | | $ | 8,799 |
| (1) | The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s stock for those awards that have an exercise price below the estimated fair value at March 31, 2026. |
|
| Schedule of information relating to options grants |
| | | | | | | | | Three Months Ended | | | March 31, | | | 2026 | | 2025 | | | | (in thousands, except per share data) | Weighted-average grant date fair value per share | | $ | 9.31 | | $ | 13.38 | Intrinsic value of options exercised | | | 1,724 | | | 7,833 | Cash received from options exercised | | | 1,850 | | | 2,068 | Total fair value of the options vested during the period | | | 11,910 | | | 10,678 |
|
| Schedule of the summary of nonvested options status |
| | | | | | | | | | Weighted-Average | | | | | Grant Date | | | Options | | Fair Value | Non-vested as of December 31, 2025 | | 2,153,209 | | $ | 15.73 | Options granted | | 1,678,489 | | | 9.31 | Options vested | | (736,104) | | | 16.18 | Options forfeited | | (23,048) | | | 16.78 | Non-vested as of March 31, 2026 | | 3,072,546 | | | 12.11 |
|
| Schedule of information relating to RSU grants and deliveries |
| | | | | | | | | | Total Fair Market | | | Total RSUs | | Value of RSUs | | | Issued | | Issued(1) | | | | | (in thousands) | RSUs outstanding at December 31, 2025 | | 1,007,433 | | | | RSUs granted | | 813,454 | | $ | 15,626 | RSUs forfeited | | (10,827) | | | | RSUs vested(2) | | (341,314) | | | | RSUs outstanding at March 31, 2026 | | 1,468,746 | | | |
| (1) | The total FMV is derived from the number of RSUs granted times the current stock price on the date of grant. |
| (2) | Of the vested RSUs, 133,119 shares of common stock were surrendered to fulfill tax withholding obligations. |
|
| Schedule of recorded share-based compensation expense under all plans |
| | | | | | | | | Three Months Ended | | | March 31, | | | 2026 | | 2025 | | | | (in thousands) | Cost of revenues | | $ | 2,456 | | $ | 2,338 | Operating expenses: | | | | | | | Selling, distribution, and marketing | | | 360 | | | 313 | General and administrative | | | 5,137 | | | 4,569 | Research and development | | | 1,321 | | | 1,173 | Total share-based compensation | | $ | 9,274 | | $ | 8,393 |
|